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Cilengitide modulates attachment and viability of human glioma
cells, but not sensitivity to irradiation or temozolomide in vitro
Abstract
Cilengitide is a cyclic peptide antagonist of integrins alphavbeta3 and alphavbeta5 that is currently being
evaluated as a novel therapeutic agent for recurrent and newly diagnosed glioblastoma. Its mode of
action is thought to be mainly antiangiogenic but may include direct effects on tumor cells, notably on
attachment, migration, invasion, and viability. In this study we found that, at clinically relevant
concentrations, cilengitide (1-100 microM) induces detachment in some but not all glioma cell lines,
while the effect on cell viability is modest. Detachment induced by cilengitide could not be predicted by
the level of expression of the cilengitide target molecules, alphavbeta3 and alphavbeta5, at the cell
surface. Glioma cell death induced by cilengitide was associated with the generation of caspase activity,
but caspase activity was not required for cell death since ectopic expression of cytokine response
modifier (crm)-A or coexposure to the broad-spectrum caspase inhibitor zVAD-fmk was not protective.
Moreover, forced expression of the antiapoptotic protein marker Bcl-X(L) or altering the p53 status did
not modulate cilengitide-induced cell death. No consistent effects of cilengitide on glioma cell migration
or invasiveness were observed in vitro. Preliminary clinical results indicate a preferential benefit from
cilengitide added to temozolomide-based radiochemotherapy in patients with O(6)-methylguanine DNA
methyltransferase (MGMT) gene promoter methylation. Accordingly, we also examined whether the
MGMT status determines glioma cell responses to cilengitide alone or in combination with
temozolomide. Neither ectopic expression of MGMT in MGMT-negative cells nor silencing the MGMT
gene in MGMT-positive cells altered glioma cell responses to cilengitide alone or to cilengitide in
combination with temozolomide. These data suggest that the beneficial clinical effects derived from
cilengitide in vivo may arise from altered perfusion, which promotes temozolomide delivery to glioma
cells.
Neuro-oNcology
Cilengitide is a cyclic peptide antagonist of integrins 
avb3 and avb5 that is currently being evaluated as a 
novel therapeutic agent for recurrent and newly diag-
nosed glioblastoma. Its mode of action is thought to be 
mainly antiangiogenic but may include direct effects on 
tumor cells, notably on attachment, migration, invasion, 
and viability. In this study we found that, at clinically 
relevant concentrations, cilengitide (1–100 mM) induces 
detachment in some but not all glioma cell lines, while the 
effect on cell viability is modest. Detachment induced by 
cilengitide could not be predicted by the level of expres-
sion of the cilengitide target molecules, avb3 and avb5, 
at the cell surface. Glioma cell death induced by cilengit-
ide was associated with the generation of caspase activ-
ity, but caspase activity was not required for cell death 
since ectopic expression of cytokine response modifier 
(crm)-A or coexposure to the broad-spectrum caspase 
inhibitor zVAD-fmk was not protective. Moreover, forced 
expression of the antiapoptotic protein marker Bcl-XL 
or altering the p53 status did not modulate cilengitide-
induced cell death. No consistent effects of cilengitide on 
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glioma cell migration or invasiveness were observed in 
vitro. Preliminary clinical results indicate a preferential 
benefit from cilengitide added to temozolomide-based 
radiochemotherapy in patients with O6-methylguanine 
DNA methyltransferase (MGMT) gene promoter meth-
ylation. Accordingly, we also examined whether the 
MGMT status determines glioma cell responses to cilen-
gitide alone or in combination with temozolomide. Nei-
ther ectopic expression of MGMT in MGMT-negative 
cells nor silencing the MGMT gene in MGMT-positive 
cells altered glioma cell responses to cilengitide alone or 
to cilengitide in combination with temozolomide. These 
data suggest that the beneficial clinical effects derived 
from cilengitide in vivo may arise from altered perfusion, 
which promotes temozolomide delivery to glioma cells. 
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High-grade gliomas represent the most frequent and malignant astroglial tumors in adults. In spite of multimodal therapeutic efforts including 
surgery, radiotherapy, and chemotherapy, most patients 
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still die within 2 years of diagnosis.1,2 This poor progno-
sis can be attributed to an intrinsic tumor cell resistance 
to the genotoxic stress induced by irradiation or classical 
chemotherapy using DNA-damaging agents, as well as 
to the diffuse invasion of single glioma cells into the sur-
rounding brain tissue, which makes efforts at curative 
surgical resection futile. Glioma cell invasiveness requires 
interaction with specific components of the extracellular 
matrix (ECM). The ECM of the brain parenchymal tis-
sue predominantly contains glycosaminoglycans. Besides 
using the host ECM, glioma cells apparently produce 
their own ECM, including components such as laminin, 
collagen types I, III, and IV, tenascin, vitronectin, and 
several types of glycosaminoglycans.3,4
Cell surface receptors of the integrin superfamily play 
a key role in mediating cell–ECM interactions. Integrins 
consist of two noncovalently associated type I trans-
membrane glycoprotein a- and b-subunits. To date, 19 
integrin a-subunits and 8 integrin b-subunits have been 
described, forming at least 25 different a/b-heterodimers. 
In addition to regulating cell–cell and cell–ECM adhe-
sion, integrins bidirectionally transmit signals important 
for cell survival, proliferation, differentiation, and motil-
ity.5 For example, ligand receptor interactions between 
ECM components and integrins activate cytoplasmatic 
tyrosine kinases, such as focal adhesion kinase, and 
their downstream effectors. The contribution of specific 
integrins to the malignant phenotype of numerous types 
of tumor has become a major area of cancer research.6,7 
Two av integrins recognizing vitronectin through an 
Arg-Gly-Asp (RGD) binding site, avb3 and avb5, are 
expressed by glioma cells and by endothelial cells asso-
ciated with new blood vessel formation in glioblasto-
mas.8–12 These av integrins are the primary target of 
cilengitide (EMD 121974), an RGD-based cyclic pep-
tide developed as an antiangiogenic drug. Based on the 
concept that avb3 and avb5 are proangiogenic recep-
tors, two av antagonists have entered clinical trials:13 
cilengitide and vitaxin, a humanized monoclonal anti-
avb3 antibody. In endothelial cells, blocking integrins 
avb3 and avb5 by RGD mimetics induces detachment 
from vitronectin-coated surfaces and results in a specific 
type of caspase-dependent apoptosis referred to as anoi-
kis.14,15 Conversely, integrin engagement by vitronectin 
provides essential survival signals and protects glioma 
cells from apoptosis.16 There is some evidence for a role 
of resistance to anoikis in malignancy in that the failure 
to undergo detachment-induced cell death may confer a 
selective advantage for tumor cells en route to invasion 
and metastasis.
Cilengitide is currently being evaluated as a novel 
therapeutic agent for recurrent and newly diagnosed 
glioblastoma.17–20 Preliminary results indicate a prefer-
ential benefit from cilengitide added to temozolomide-
based radiochemotherapy in patients with O6-methyl-
guanine DNA methyltransferase (MGMT) promoter 
methylation.19 In the present study, we characterized the 
biological effects of cilengitide on glioma cell lines that 
express different levels of the target molecules, avb3 
and avb5, and that can be modulated regarding their 
MGMT status and thus sensitivity to temozolomide.
Materials and Methods
Reagents
The RGD peptide cyclo-(Arg-Gly-Asp-DPhe-NMe-
Val)21 (cilengitide, EMD 121974) was kindly provided 
by Merck KGaA (Darmstadt, Germany). Temozolo-
mide was supplied by Schering Plough (Kenilworth, NJ, 
USA). Ad-p53 was a kind gift from B. Vogelstein (How-
ard Hughes Medical Institute, Johns Hopkins Oncol-
ogy Center, Baltimore, MD, USA). Propidium iodide 
(PI) and the murine IgG1 isotype control were obtained 




coumarin), from Bachem (Weil am Rhein, Germany). 
Antibodies used were anti-avb3 (LM609, Chemicon, 
Temecula, CA, USA), anti-avb5 (P1F6, Chemicon), 
anti-av (17E6, Merck), anti-MGMT (Alpha Diagnostic, 
San Antonio, TX, USA), and anti-actin (sc-1616, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA).
Cell Culture
The glioma cell lines were kindly provided by N. de 
Tribolet (Lausanne, Switzerland) and have been charac-
terized previously.22,23 LNT-229 p53 small interfering 
RNA (siRNA) cells, MGMT-expressing LNT-229 cells, 
and Bcl-XL–expressing or cytokine response modifier 
(crm)-A–expressing LN-18 and T98G cells, as well as 
neomycin or puromycin-resistant control cells, were 
generated as described.24–27 NIH-3T3 murine fibroblast 
cells were from the American Type Culture Collection 
(Manassas, VA, USA). All cell lines were maintained 
at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s 
medium (Gibco, Eggenstein, Germany) supplemented 
with 10% fetal calf serum, 2 mM glutamine, 100 IU/
mL penicillin, and 100 mg/mL streptomycin. Condi-
tioned medium was generated by incubating NIH-3T3 
cells in serum-free medium for 48 h and stored at –80°C. 
Primary ex vivo glioma cell cultures were prepared from 
surgical samples.28 Adenoviral infection was performed 
as previously described.29
MGMT Gene Silencing
To silence MGMT gene expression, short-hairpin RNA 
(shRNA) sequences were cloned into the pSUPER-puro 
vector.30 Certain sequences below are identified as cod-
ing sequences by boldface type; sequences in regular 
type participate in hairpin formation. The sequences 
were as follows: MGMT shRNA, 5'-GATCCCC 
AAGGTTGTGAAATTCGGAGAATTCAAGAGA 
TTCTCCGAATTTCACAACCTTTTTTTGGAAA-3' 
(nucleotides 936–958; Entrez gene ID 11798); and 
scrambled shRNA, 5'-GATCCCCACTACCGTTGT-
TATAGGTCTTCAAGAGAGACCTATAACAACG-
GTAGTTTTTTGGAAA-3' without homology to any 
known expressed mRNA. LN-18 and T98G glioma 
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Adhesion Assays
Cells were detached with nonenzymatic cell dissociation 
solution (Sigma-Aldrich) and allowed to adhere for 2 h 
on 96-well plates coated with human vitronectin (0.5 
mg/well) or fibronectin (1.0 mg/well; both R&D Sys-
tems, Minneapolis, MN, USA) in the presence of dif-
ferent cilengitide concentrations. Attached cells were 
stained with crystal violet and quantified by measuring 
the absorbance at 560 nm. Alternatively, the detached 
cells were incubated with cilengitide, control peptide, or 
integrin antibodies, and their attachment was monitored 
by phase-contrast microscopy.
SDS-PAGE and Immunoblotting
For the preparation of protein extracts, floating and 
attached cells were harvested and lysed in a buffer con-
taining 50 mM Tris-HCl, 120 mM NaCl, 5 mM EDTA, 
0.5% Nonidet-P40, 2 mg/mL aprotinin, 10 mg/mL leu-
peptin, 100 mg/mL phenylmethylsulfonyl fluoride, 50 
mM NaF, 200 mM NaVO5, and phosphatase inhibitor 
cocktails I and II (Sigma-Aldrich). Protein concentra-
tions were determined using a Bradford assay (Bio-Rad, 
Hercules, CA, USA). Equal amounts of total protein 
were fractionated under reducing conditions by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and electroblotted on nitrocellulose (Amersham, 
Braunschweig, Germany). Membranes were blocked in 
Tris-buffered saline containing 5% skim milk and 0.1% 
Tween-20 and incubated with the appropriate primary 
and secondary antibodies. Immune complexes were 
detected by enhanced chemiluminescence (Pierce, Rock-
ford, IL, USA).
Invasion and Migration Assays
Matrigel invasion assays were performed as described 
previously,31,32 with some modifications. Briefly, 4 3 105 
cells were plated on transwell chambers (12 mm diam-
eter, 12-mm pore size; Corning Costar, Acton, MA, 
USA) precoated with 10 mg/cm2 Matrigel (Matrigel 
Basement Membrane Matrix, BD Biosciences, Bedford, 
MA, USA). NIH-3T3–conditioned medium was used as 
a chemo attractant. Following a 12-h incubation, nonin-
vading cells were removed with cotton swabs, and invad-
ing cells were trypsinized and counted using the Cell-
Titer-Glo Luminescent Cell Viability Assay (Promega, 
Madison, WI, USA).33 Cell migration toward NIH-3T3– 
conditioned medium was assayed using modified Boyden 
chambers (6.5-mm diameter, 8-mm pore size; Corning 
Costar). After 16 h, migrated cells were fixed, stained, 
and counted by microscopic examination.
Statistical Analysis
Usually, experiments were performed three times, with 
similar results. Significance was tested using the two-
tailed Student’s t-test. Synergy was assessed by the frac-
tional product method.34
cells were transfected with either pSuper-puro-MGMT 
or pSUPER-puro-scrambled using Metafectene PRO 
(Biontex, Martinsried, Germany). Stable cell lines were 
generated by puromycin selection (5 mg/mL). Surviving 
cells were expanded, and MGMT downregulation in the 
selected cell pools was controlled by immunoblot.
Growth and Viability Assays
For the evaluation of cell proliferation, glioma cells were 
plated in 96-well flat-bottom plates and 24 h later treated 
with serum-free medium alone or with cilengitide. The 
cells were pulse-labeled with 5-bromo-2-deoxyuridine 
(BrdU) for the last 4 h and then analyzed using the 
Amersham Cell Proliferation Biotrak enzyme-linked 
immunosorbent assay system (GE Healthcare, Buck-
inghamshire, UK). To capture overall proliferation and 
to exclude the detachment effect, labeling medium was 
removed by air drying as recommended by the manu-
facturer for suspension cells. Acute cytotoxicity assays 
involved the exposure of glioma cells seeded at an appro-
priate density to increasing concentrations of cilengitide 
(0.1 mM to 1 mM) for different periods of time. Viability 
was assessed by PI staining and flow cytometry (CyAn 
ADP flow cytometer, Dako, Cambridge, UK; Summit 
software version 4.3, Dako, Fort Wayne, IN, USA). Clo-
nogenic survival assays were performed by seeding 500 
cells in six-well plates and exposing them to cilengitide 
or temozolomide for 24 h, followed by centrifugation at 
1,200 rpm and further observation in drug-free com-
plete medium for 7–21 days. Cell density or colonies 
were assessed using crystal violet staining. Colonies of 
more than 50 cells were counted. For cell cycle analy-
sis, floating cells and adherent cells detached by trypsin 
treatment were collected, fixed in ethanol (70% vol/vol), 
and stained with PI (50 mg/mL) diluted in phosphate-
buffered saline (PBS) containing RNase A (100 mg/mL). 
DNA content was analyzed by flow cytometry. In some 
experiments, cells were irradiated at 0.5, 1, 2, or 8 Gy 
(137Cs source, Gammacell 40 Exactor, MDS Nordion, 
Ottawa, ON, Canada). Caspase activity was assessed 
using the fluorescent substrate DEVD-amc as previously 
described26 and a Mithras LB 940 microplate reader 
(Berthold Technologies, Bad Wildbad, Germany). Cells 
were grown for several time periods in phenol red-free 
medium containing different cilengitide concentrations 
or CD95 ligand as a positive control. Subsequently, cells 
were lysed and exposed to DEVD-amc, both by adding 
the corresponding solutions.
Quantification of Integrin Expression
Cells were detached with nonenzymatic cell dissociation 
solution (Sigma-Aldrich, St. Louis, MO, USA) and incu-
bated with primary antibody anti-avb3, anti-avb5, or 
isotype control diluted in PBS containing 0.5% bovine 
serum albumin, 2 mM EDTA, and 1 mM MgCl2. After 
exposure to the fluorescently conjugated secondary anti-
body, the cells were analyzed by flow cytometry.
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Results
Expression of avb3 and avb5 Integrins  
on Glioma Cell Lines
To evaluate the presence of the target molecules of 
cilengitide on the cell surface, avb3 and avb5 integrin 
expression was assessed by flow cytometry. Confirming 
our previous data,35 avb3 expression varied substan-
tially among the cell lines tested. U87MG, LNT-229, 
and LN-308 cells revealed high avb3 levels, whereas 
LN-18 and LN-319 were negative. avb5 was expressed 
by all glioma cell lines examined (Table 1). As verified 
in LN-308 cells, avb3 and avb5 integrin expression did 
not change in response to prolonged cilengitide exposure 
(1 mM and 10 mM, 24 h; data not shown).
Modulation of Glioma Cell Attachment  
and Viability by Cilengitide
We confirmed that the adhesion of U87MG, LN-308, 
LN-18, T98G, and LNT-229 cells to vitronectin and, 
to a lesser extent, to fibronectin was concentration- 
dependently impaired by cilengitide (Fig. 1A). Both vit-
ronectin and fibronectin are ligands for integrin avb3, 
whereas integrin avb5 exclusively binds to vitronectin. 
The lesser detachment on fibronectin-coated wells versus 
vitronectin can be explained by the fact that, apart from 
avb3, other integrins expressed by glioma cells, such as 
a5b1, may bind to fibronectin as well. Representa-
tive photomicrographs of cilengitide-treated U87MG, 
LN-308, LN-18, T98G, and LNT-229 cells are shown 
in Fig. 1B. The time course of cilengitide induced in 
LN-308 cells is exemplified in Fig. 1E. Whereas there 
was differential sensitivity to cilengitide-induced detach-
ment, the control peptide RAD never induced detach-
ment in any cell line tested. A comparative analysis of 
the data summarized in Table 1 and Fig. 1 shows no 
apparent link between the sensitivity to cilengitide-
induced detachment and integrin expression. In contrast 
to cilengitide, antibodies to integrins avb3 or avb5 did 
not detach monolayer cultures. This was probably due 
to steric inability for the antibodies to reach their target. 
When the paradigm was changed to expose detached 
cells to cilengitide or the antibodies and then monitor 
their attachment, either cilengitide or antibodies to av 
or avb3, but not the control peptide or the antibody to 
avb5, prevented the attachment of LN-308 cells (Fig. 
2).
To confirm that the effects of cilengitide were not 
restricted to long-term cultured cell lines, we performed 
similar studies in five primary ex vivo glioma cell cul-
tures. There was strong detachment in three cell lines, 
whereas two did not detach (data not shown). BrdU 
incorporation assays performed over a time span of 72 h 
revealed that proliferation in U87MG, LN-308, LN-18, 
T98G, and LNT-229 cells was differently modulated by 
cilengitide: at 72 h posttreatment, BrdU incorporation 
was decreased by 35% in U87MG cells but increased by 
30% in LN-308 cells (Fig. 1C). Flow cytometric analy-
sis of cell cycle progression failed to identify any spe-
cific change of cell cycle distribution in either cell line 
in association with these changes in proliferation (data 
not shown).
We assessed whether cilengitide exposure resulted 
not only in detachment but also in a loss of viability. 
At 6–8 h after exposure, a PI-positive cell population of 
up to 15%–35% was detected. At later time points up 
to 120 h after exposure, there was no further increase 
in dead cells in either U87MG, LN-308, or LNT-229 
cells. In contrast, a rising percentage of cells taking up 
PI was observed in T98G and LN-18 cells (Fig. 1D). In 
contrast, the viability of cells treated with the control 
peptide RAD did not differ from untreated controls; for 
example, there were 93.1% PI-negative LN-18 cells at 
72 h after treatment with 10 mM RAD peptide versus 
92.2% PI-negative untreated controls, and 80.5% versus 
81.2% for T98G cells. To exclude a reduced stability 
of cilengitide in the cell culture in prolonged exposure 
assays, LN-308 cells were treated with cilengitide pre-
incubated in medium at 37°C for 24 h. In these experi-
ments, cellular viability and detachment did not differ 
from previous experiments with freshly dissolved sub-
stance (data not shown).
We sought to define the biochemical mode of the 
limited amount of cell death induced by cilengitide. 
Cilengitide did not induce DEVD-amc–cleaving cas-
pase activity in U87MG, LN-308, or LNT-229 cells and 
induced  little activity in LN-18 cells. In T98G cells, cas-
pase activity was detectable at 24 h and 48 h, although 
not at 6 h, after cilengitide exposure (Table 2). Ectopic 
expression of crm-A in LN-18 or T98G cells or of the 
antiapoptotic protein marker Bcl-XL in LN-18 cells did 
not modify detachment, viability, or cell cycle distribu-
tion after cilengitide treatment (0.1 mM, 1 mM, 10 mM, 
100 mM, or 1 mM, for 8 h, 24 h, 72 h, or 120 h; Table 
3, data not shown). Similarly, although caspase activ-
ity was nullified, the broad-spectrum caspase inhibitor 
zVAD-fmk failed to prevent cell death (Table 3).
The spectrum of cell lines used had already indi-
cated that the effects of cilengitide were independent of 
Table 1. Cell surface avb3 and avb5 levels determined by flow 
cytometry and cilengitide-induced detachment
 avb3  avb5 OD OD 
Cell Line (SFI) (SFI) (1 mM) (%) (10 mM) (%)
A172 1.54 2.13 63.9 13.2
LN-18 1.07 1.85 98.9 64.8
LNT-229 25.81 1.85 91.9 84.8
LN-308 14.5 1.54 99.0 71.2
LN-319 1.07 3.29 95.5 34.3
LN-428 2.07 2.95 86.3 55.9
T98G 4.9 1.78 96 72.8
U87MG 15.56 1.91 74 57.1
Abbreviations: SFI, specific fluorescence index; OD, optical density.
Integrin expression was determined by flow cytometry and is expressed as the mean 
specific fluorescence index. Residual nondetached cells after exposure to cilengitide at 
1 mM or 10 mM for 24 h were stained with crystal violet and are quantified as optical 
densities relative to untreated cell cultures.
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Fig. 1. effects of cilengitide on the adhesion, growth, and viability of cultured human glioma cells. (A) U87MG, LN-308, LN-18, T98G, 
and LNT-229 cells were cultured in the absence or presence of cilengitide for 2 h. Adherence was measured by crystal violet staining and is 
expressed in percentages relative to untreated cells. **p , 0.01, vitronectin versus fibronectin. (B) Cells were exposed to cilengitide at 0.1 
mM, 1 mM, or 10 mM for 24 h and monitored by phase-contrast microscopy. Scale bars, 100 mm. For LN-18 and T98G cells, an alanine-
substituted peptide (RAD) served as an additional nonbinding control. (C) U87MG, LN-308, LN-18, T98G, and LNT-229 cells treated with 
cilengitide (10 mM) for 12 h, 24 h, 48 h, or 72 h were assessed for proliferation by BrdU incorporation (mean 6 SeM; n 5 3). (D) The rela-
tive proportion of living (PI-negative) pooled adherent and detached cells at 6 h and 72 h after cilengitide exposure. (e) The time course of 
detachment in the presence of cilengitide (10 mM) in LN-308 cells. Scale bar, 100 mm.
Table 2. DeVD-amc (N-acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin)-cleaving cas-
pase activity after 24 h of cilengitide treatment
 Cilengitide Concentration 
Cell Line Time Period 0.1 mM 1 mM 10 mM 100 mM 1 mM
U87MG 24 h 100.9 102.4 101.4 100.7 102.0
LN-308 24 h 98.6 102.9 102.3 101.8 102.5
LN-18 24 h 99.5 102.6 107.1 106.7 110.0
T98G 6 h 97.2 100.5 99.8 97.9 101.5
 24 h 105.6 131.9 144.5 140.8 154.4
 48 h 92.4 144.1 192.2 202.1 226.2
LNT-229 24 h 94.7 93.1 89.2 90.2 87.6
Caspase activity in all floating and adherent cells was assessed by DeVD-amc cleavage. Data are expressed as 
percentages relative to untreated control cells.
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the endogenous p53 status of the cell lines22 (Table 1) 
because both p53 wild-type and p53-deficient cell lines 
were susceptible to cilengitide-induced detachment. To 
formally confirm this, we took a twofold approach: 
we assessed the effects of cilengitide by phase-contrast 
microscopy and cell cycle analysis in p53 wild-type LNT-
229 cells depleted of p53 by siRNA or p53 null LN-308 
cells transduced with an adenoviral vector expressing 
wild-type p53.24,29 Neither intervention altered the cel-
lular sensitivity to cilengitide in these assays (data not 
shown).
Modulation of Glioma Cell Motility  
and Invasiveness by Cilengitide
The infiltrative behavior of glioma cells is a function of 
two phenotypes: migration and invasiveness. Migration 
refers to the capacity of locomotion, whereas invasion 
involves migration plus a degradative function achieved 
by the liberation of proteolytic enzymes. Using a classi-
cal migration assay, cilengitide induced a concentration-
dependent increase in migrated tumor cell numbers in 
U87MG and LNT-229 cells. The migration of LN-308 
cells in that assay was unaffected by cilengitide. Using 
a classical Matrigel invasion assay, the invasiveness of 
LN-308 glioma cells was significantly reduced by cilen-
gitide, to an extent that could not be attributed to the 
small cytotoxic effect observed after short-term incuba-
tion. In contrast, in U87MG or LNT-229 cells, there was 
no such effect (Table 4).
Targeted Alterations of the MGMT Status Do Not 
Modulate Glioma Cell Sensitivity to Cilengitide
The apparent benefit derived from cilengitide when com-
bined with radiotherapy and temozolomide specifically 
for patients with MGMT promoter methylation in study 
EMD 121974-01019 necessitated further studies on the 
relation between MGMT gene promoter status and 
cilengitide sensitivity in our cell culture paradigms. To 
this end, we studied either MGMT-positive T98G and 
LN-18 cells depleted of endogenous MGMT by shRNA 
or MGMT-negative LNT-229 cells transfected with an 
MGMT plasmid (Fig. 3A). MGMT depletion shifted the 
half-maximal effective concentration (EC50) for temo-
zolomide in clonogenic cell death assays from 500 to 25 
Fig. 2. Cilengitide and antibodies to av or avb3 integrin, but not 
control peptide or antibodies to avb5, prevent the attachment of 
LN-308 cells. LN-308 cells were detached nonenzymatically, plated 
in the presence of cilengitide, RAD control peptide (10 mM), or 
antibodies to av (10 mg/mL), avb3 (10 mg/mL), avb5 (10 mg/mL), 
or IgG1 isotype control (10 mg/mL) and monitored for attachment 
for 24 h. Scale bar, 100 mm.
Table 3. No protection from cell death afforded by cytokine response modifier (crm)-A, the 
antiapoptotic protein marker Bcl-XL, or the broad-spectrum caspase inhibitor zVAD-fmk
 Cilengitide Concentration 
Cell Line Control 0.1 mM 1 mM 10 mM 100 mM 1 mM
T98G puromycin 96.1 92.7 86.7 76.6 75.9 73.5
T98G crm-A 93.4 91.5 84.2 78.2 80.5 79.1
T98G 96.2 95.8 88.5 80.6 85.1 84.3
T98G zVAD-fmk 94.8 93.2 83.4 78.2 84.7 84.0
LN-18 puromycin 95.4 94.0 90.6 88.7 76.4 76.2
LN-18 crm-A 93.5 92.9 79.5 79.3 57.7 50.1
LN-18 neomycin 92.5 88.1 88.3 61.0 60.3 50.5
LN-18 Bcl-XL 91.4 90.1 82.8 57.1 56.9 41.3
LN-18 92.8 87.9 84.0 53.9 51.4 45.1
LN-18 zVAD-fmk 91.7 89.1 84.3 65.5 61.4 57.9
The percentage of living (propidium iodide negative) cells at 24 h after cilengitide exposure was determined in glioma 
cell cultures engineered to express crm-A or Bcl-XL or coexposed to zVAD-fmk (50 mM).
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mM in LN-18 and from 50 to 25 mM in T98G cells, 
whereas the MGMT gene transfer into LNT-229 cells 
shifted the EC50 concentration from 10 to 150 mM (Fig. 
3B).27 These paired cell lines were exposed to increasing 
cilengitide concentrations (0.1 mM, 1 mM, 10 mM, 100 
mM, 1 mM) for different periods of time (6 h, 24 h, 72 
h, 120 h) and assayed by phase-contrast microscopy and 
cell cycle analysis. In summary, neither changes induced 
by cilengitide in cell cycle distribution nor cell viabil-
ity depended on the MGMT expression levels. Overall, 
these studies did not reveal a modulation of cilengitide 
sensitivity by altering MGMT expression. Representative 
data are shown in Fig. 3C. Appropriate control experi-
ments were performed to ascertain that the modulation 
of MGMT expression in these glioma cell lines did not 
affect the cell surface expression of the target molecules 
of cilengitide, avb3, and avb5 (data not shown).
Combined Modality Treatment Using  
Cilengitide and Irradiation or Temozolomide:  
Role of the MGMT Status
The presence of ECM increases resistance to cell- 
damaging agents such as ionizing radiation.36,37 In 
LN-308 glioma cells irradiated at 8 Gy, the irradiation-
induced G2/M arrest was unaffected by cilengitide. 
Clonogenic survival assays indicated an additive effect 
of irradiation at 0.5, 1, or 2 Gy when combined with 
cilengitide at 10 mM in LN-308 cells (Fig. 4A). We also 
assessed the effects of combining cilengitide and temo-
zolomide in clonogenic survival assays. At certain com-
binations of concentrations of both agents, there was a 
synergistic suppression of clonogenic survival in LN-308 
cells as defined by the fractional product method (Fig. 
4B).34 We examined whether a similar synergistic effect 
may be detected depending on the targeted MGMT 
alterations in LN-18, T98G, and LNT-229 cells. Using 
fixed concentrations of cilengitide and either equimolar 
or equipotent concentrations of temozolomide, we com-
monly observed additive but rarely synergistic activity of 
the combination (Fig. 5).
Discussion
Current efforts at improving the progression-free sur-
vival for patients affected by glioblastoma include 
the addition of novel agents to the standard of care 
of involved field radiotherapy plus concomitant and 
adjuvant temozolomide.1 Among these, antiangiogenic 
Table 4. Migration and Matrigel invasion: differential modulation 
by cilengitide
Measure U87MG LN-308 LNT-229
Migration 256 6 19** 114 6 13 408 6 49*
Invasiveness 114 6 17     12 6 6* 79 6 20
U87MG, LN-308, and LNT-229 cells were exposed to cilengitide (10 mM) and 
migration and invasiveness were assessed. Data are expressed as mean percentages 
relative to untreated control cultures and SeM, with triplicate samples from a 
representative experiment.
*p , 0.05, **p , 0.01 relative to control.
Fig. 3. Glioma cell sensitivity to cilengitide is not related to meth-
ylguanine DNA methyltransferase (MGMT) expression. (A) Short-
hairpin RNA-mediated MGMT (shMGMT) gene silencing (LN-18, 
T98G) or MGMT transgene expression (LNT-229) was verified by 
immunoblot. (B) MGMT depletion shifted eC50 for TMZ in clono-
genic cell death assays from 500 to 25 μM in LN-18, from 50 to 25 
μM in T98G cells, but the MGMT gene transfer into LNT-229 cells 
shifted the eC50 concentration from 10 to 150 μM. (C) After 72 h 
incubation with cilengitide (10 mM), LN-18, T98G, and LNT-229 
cells were examined morphologically (left; scale bars, 100 mm) or 
stained with PI for the analysis of DNA content (right). Abbrevia-
tion: TMZ, temozolomide
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to benefit from temozolomide.38 The mechanisms under-
lying this apparent interrelation between the response 
to cilengitide and the MGMT status in the tumor tissue 
have remained obscure. Using genetically engineered cell 
lines, we determined that targeted alterations in MGMT 
expression do not alter cellular responses to cilengitide 
(Fig. 3). Depending on the cell line studied, temozolo-
mide and irradiation had synergistic or additive, but 
never antagonistic, effects when combined with cilen-
gitide in clonogenic survival assays (Fig. 4). Moreover, 
when equipotent concentrations of temozolomide were 
used in parallel assays of MGMT-deficient and MGMT-
proficient LNT-229 cells, there were similar inter actions 
with cilengitide (Fig. 5). Altogether, these studies did 
not lead to the identification of specific pharmaco-
logical interactions of temozolomide and cilengitide in 
Fig. 4. Suppression of clonogenic survival by temozolomide or irra-
diation in combination with cilengitide. LN-308 cells were irradi-
ated (0.5 Gy, 1 Gy, 2 Gy) and exposed to cilengitide (Cil, 10 mM; 
A) or cotreated with temozolomide (TMZ, 10 mM; B) and assessed 
for clonogenic survival (mean and SeM, n 5 3). According to the 
fractional product method,34 the predicted effect of cotreatment 
expressed as the product of the surviving fractions with single 
agent treatment is compared with the observed effect.
Fig. 5. Methylguanine DNA methyltransferase (MGMT)-indepen-
dent coinhibition of glioma cell growth by temozolomide (TMZ) 
and cilengitide. LN-18 scrambled short-hairpin RNA (shRNA) con-
trol (A), T98G scrambled shRNA control (C), LNT-229 neomycin 
(e), or LN-18 and T98G MGMT-knockdown (B, D) or LNT-229 
MGMT-overexpressing (F) cells were treated with temozolomide 
(300 mM for LN-18 scrambled, 10 mM for LN-18 shMGMT, 50 
mM for T98G scrambled, 25 mM for T98G shMGMT, 8 mM for 
LNT-229 neo, 100 mM for MGMT-overexpressing LNT-229 cells) 
or cilengitide (10 mM) or both and assessed for clonogenic survival 
(mean and SeM, n 5 3).
agents such as bevacizumab, enzastaurin, or cilengitide 
have received particular attention. To understand how 
such agents may contribute to a favorable clinical out-
come in patients with glioblastoma, it is important to 
dissect the molecular effects of such agents on glioma 
cells versus various host target cell populations, notably 
endothelial cells.
We here characterize strong detaching properties of 
clinically relevant concentrations of cilengitide in the 
majority of human glioma cell lines, associated with a 
moderate loss of viability (Fig. 1). This moderate loss of 
viability was unaffected by caspase inhibition or ectopic 
expression of Bcl-XL, suggesting that cilengitide-induced 
glioma cell death does not involve death-receptor– 
dependent or mitochondrial apoptosis pathways (Tables 
2 and 3). This contrasts with human endothelial cells, 
which were reported to detach, to activate caspases, 
and to undergo apoptosis following cilengitide treat-
ment.14 The effects on migration and invasiveness were 
highly variable across the three cell lines examined in 
more detail (Table 4). It remains a matter of controversy 
whether these assays are suitable to preclinically assess 
the clinical potential of agents such as cilengitide in 
vitro.
A phase II trial of cilengitide added to radiotherapy 
and temozolomide in patients with newly diagnosed 
glioblastoma appeared to provide a progression-free sur-
vival advantage specifically in patients with MGMT gene 
promoter methylation in the tumor19 who are most likely 
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to temozolomide anyway (the “methylators”) but not 
those exhibiting primary resistance to temozolomide 
(the majority of the “nonmethylators”). If cilengitide 
eventually does find a place in the standard of care of 
glioblastoma, it will become a challenging task to dissect 
to what extent effects on the glioma cells contribute to 
the clinical activity of this agent.
vitro. Alternative explanations for the beneficial clinical 
effects derived from cilengitide in patients with MGMT-
promoter–methylated tumors must therefore be sought. 
Likely, cilengitide will inhibit angiogenesis and therefore 
induce a more mature vessel phenotype that improves 
tumor perfusion and thus promotes temozolomide deliv-
ery to glioma cells in vivo. Accordingly, more temozolo-
mide will benefit those patients likely to be responsive 
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